Topo 2 alpha test FDA approved

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

TOP2A FISH pharmDx assay has received FDA approval for use as an adjunct to existing clinical and pathological information in determining the prognosis for patients with relatively high-risk breast cancer.

ROCKVILLE, Maryland-Dako’s TOP2A FISH pharmDx assay has received FDA approval for use as an adjunct to existing clinical and pathological information in determining the prognosis for patients with relatively high-risk breast cancer.

It is the first approved test for assessing clinical breast cancer tissue specimens for amplifications and deletions of the topoisomerase 2-alpha gene.

This information aids physicians in evaluating the prognosis for breast cancer patients, since patients with normal topo 2-alpha status have a better outcome than patients with topo 2-alpha gene amplifications or deletions.

The test is suitable for breast cancer patients who are premenopausal or for whom tumor characteristics, such as tumor size or lymph node involvement, suggest a higher likelihood of tumor recurrence or decreased survival.

Topo 2-alpha appears to be a molecular target for the pharmacologic action of anthracyclines, with implications for use of these agents, the Danish-based company said. In a new analysis of the BCIRG 006 trial data, anthracyclines were beneficial only in the subset of patients who had co-amplification of HER2 and the topo 2-alpha gene (see Oncology News International January 2008, page 1).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.